Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT05838066, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. Planned enrolment is 880 participants (estimated). The study started in 2023-07-23 and primary completion is expected in 2025-07-31. No results have been posted on ClinicalTrials.gov.